Optimizing Vancomycin Dosing in Obese and Morbidly Obese Patients with MRSA Infections

Eddie Grace*, Nancy Hope Goodbar and Jaime A. Foushee
Department of Pharmacy Practice, Presbyterian College School of Pharmacy, 307 North Broad Street, Clinton, USA

Abstract

Approximately 275,000 of these hospitalizations were due to Methicillin-resistant Staphylococcus aureus (MRSA) infections which resulted in over 19,000 deaths. Since VCN's introduction over 6 decades ago, it has been studied in various patient populations such as those with renal disease, burns, and cystic fibrosis. However, until recently, extremely limited data has been available for the use of VCN in obese patients. Due to the differences in VCN pharmacokinetics in obese patients compared to non-obese patients, use of PK parameters in obese patients which were originally derived from non-obese patients results in erroneous dosing of VCN leading to clinical failures and increased incidence of adverse effects. PK parameters such as vancomycin clearance, volume of distribution, protein binding, and creatinine clearance (CrCl) in obese patients will be discussed in addition to studied methods to optimize vancomycin dosing in obese patients by using loading doses, weight based dosing, and area under the curve to minimum inhibitor concentration ratio (AUC:MIC). Due to the variability in dosing of obese patients compared to non-obese patients, VCN maximum doses and the incidence of nephrotoxicity will also be discussed.

Keywords: Obesity; Vancomycin; Pharmacokinetics; Mrsa; Loading dose; Nephrotoxicity

Introduction

In the United States (U.S.), greater than one-third of the adult population over the age of twenty is classified as obese. Obesity accounts for 20% of individuals under the age of 20% and accounts for 40% of adults over the age of sixty, thus signaling an increase in rates of obesity with increased age [1]. In 1990, all states within the U.S. had a prevalence of obesity of less than 15%. Ten years later, the incidence of obesity had increased to nearly 25% in some states. In 2010, obesity accounted for up to 34% of the population in each state. World-wide increases in rates of obesity have resulted in increased incidence of heart diseases, type 2 diabetes mellitus, and certain cancers [1]. The rising rates of these comorbidities such increases healthcare utilization, as these patients are more susceptible to infections requiring hospitalization and intravenous antibiotics. The Centers for Disease Control and Prevention (CDC) estimated that the medical cost related to obesity is approximately 147 billion U.S. dollars annually.

In 2005, over 475,000 hospitalizations in the U.S. were attributed to Staphylococcus aureus infections [2]. Approximately 275,000 of these hospitalizations were due to Methicillin-resistant Staphylococcus aureus (MRSA) infections which resulted in over 19,000 deaths [2]. [http://www.cdc.gov/mrsa/statistics/index.html]. Due to the rising rate of MRSA infections in both the community and healthcare settings, the use of antibiotics active against MRSA also has been on the rise. Among MRSA active antibiotics, vancomycin (VCN) is often considered the antibiotic of choice for patients hospitalized with suspected or documented MRSA infections. Since the introduction of VCN over 6 decades ago, it has been studied in various patient populations including renal disease, burns, and cystic fibrosis. Until recently, extremely limited data has been available regarding the use of VCN in obese patients. Use of PK parameters originally derived from non-obese patient in an obese population may result in erroneous dosing of VCN, due to the differences in VCN PKs in obese patients compared to non-obese patients. This may result in increased rates of clinical failures and an increased incidence of VCN adverse effects and resistance. This article will discuss PK parameters in obese patients, including VCN clearance (VCl), volume of distribution (Vd), protein binding, and creatinine clearance (CrCl), as well as methods to optimize VCN dosing in this patient population. Due to the variability in dosing of obese patients compared to non-obese patients, VCN maximum doses and the incidence of nephrotoxicity will also be discussed.

Altered Pharmacokinetics of Vancomycin in Obese Patients

VCN PKs which have been studied in obese patients including altered Vd due to excess adipose tissue and protein binding. VCN renal elimination has also been studied as it relates to CrCl and VCl [3-5]. Based basic PK principles, both Vd and VCI play a role in the elimination constant (Ke) which directly relates the dose (D) and dosing interval (T) [6].

The volume of distribution of a drug affects both the loading dose needed to achieve a therapeutic drug level, and the maintenance dose required to maintain a target drug concentration in serum following the loading dose [6]. The variability in VCN Vd variability estimate in previously published studies is likely due to the varying hypotheses surrounding estimates of water content in adipose tissue. The most agreed on estimate is based on aminoglycoside studies in obese patients, which estimated that water content accounts for approximately 30-40% of adipose tissue weight [7]. Studies in non-obese and obese patients have provided a wide range of values for VCN Vd per kg ranging from...
0.49 L/Kg to 1.25 L/Kg based on total body weight (TBW), with specific estimates in obese and morbidly obese patients ranging from 0.26 L/Kg (TBW) to as high as 1.7 L/Kg (TBW) [8–10]. In addition, some studies suggest that TBW best correlates with Vd while others have shown that replacing TBW with IBW or lean body weight (LBW) does not improve the relationship of weight to VCN Vd [4,10]. Utilizing an average Vd of 0.7 L/Kg can result in an underestimation of the total Vd if IBW is used. Perhaps similar to aminoglycosides, VCN Vd can be best estimated using an adjusted body weight (ABW) or by use of a lower Vd/Kg while continuing to utilize TBW; however, more studies are needed to determine if the use of ABW is appropriate. VCI has shown to be increased in obese patients due several physiological changes compared to non-obese patients [3]. VCI has shown to be approximately 2.5 fold higher in obese patients when compared to non-obese patients [9,11]. Using the Cockcroft-Gault equation to estimate CrCl (which is the standard method used to estimate drug elimination) TBW best correlated with CrCl and total VCI [3,11–14].

In addition to altered VCN Vd in obese patients, certain proteins such as α1-acid glycoprotein (AAG) may be elevated in obese patients resulting in an increased amount of VCN bound to serum proteins and lower than expected concentration of unbound (free) VCN in serum [15]. Other studies have shown that other proteins which bind VCN in serum, such as albumin, may be elevated in obese patients compared to non-obese patients [16]. Based on the increased Vd and VCI, an increase in protein binding would result in significant decreases in unbound VCN serum concentration in obese patients leading to a significant increase in clinical failures despite small variations in total VCN concentrations compared to non-obese patients [17].

Altered Vancomycin Pharmacodynamics and Dosing in Obesity

Vancomycin AUC:MIC ratio and weight based dosing for obesity

With the PK and pharmacodynamic (PD) changes of VCN seen in the obese population, as well as the dependence of the areas under the concentration curve (AUC) calculation CrCl, VCI, and Vd, it is evident that body weight is a common denominator in all of these factors. In one study which evaluated initial VCN pharmacokinetic studies in obese patients, TBW had the strongest correlation with Vd and VCI compared to IBW and ABW [11]. No significant differences in weight-based daily doses (mg/Kg/day) were noted when comparing non-obese patients to obese patients. Similar studies which have examined the VCN average weight based daily dose (mg/Kg/day using TBW) needed to achieve a therapeutic VCN trough levels found that doses for morbidly obese and non-obese patients did not significantly differ [11]. These findings suggest the use of TBW in calculating VCN mg/Kg doses for non-obese and obese patients.

The use of TBW and not ABW or IBW should be used in calculating doses at least initially until VCN serum levels can be obtained to adjust doses based on the patient specific PK parameters. This approach is supported by the Guidelines for the Therapeutic Monitoring of Vancomycin in Adult Patients which was published in 2009 by the American Society of Health-System Pharmacists (ASHP), Infectious Diseases Society of America (IDSA), and Society of Infectious Diseases Pharmacists (SIDP) [18]. The guidelines recommend a maintenance dose of 15-20 mg/Kg (based on TBW) every 8-12 hours in patients without renal disease in effort to try to achieve an AUC:MIC ratio of >400 (assuming the MIC is ≤ 1 mg/Kg) [18].

The clinical utility of maintaining the AUC:MIC>400 has been endorsed by the ASHP/IDSA/SIDP as the PD parameter that can best predict the efficacy and clinical success of VCN with the best correlation to bacterial killing [19]. Although monitoring serum trough levels are common practice, the utility of the serum trough levels serve as a surrogate marker of AUC [19]. In a study including patients with lower respiratory tract infections, the patients who achieved an AUC:MIC ratio >400 exhibited bacterial eradication after 10 days compared with >30 days in those patients who did not reach the AUC:MIC ratio goal [20]. Despite the recommendations in the above mentioned guidelines, the majority of clinicians are hesitant to use such high weight based doses, especially in obese patients who may require more than 4 grams of VCN daily to maintain the desired AUC:MIC, as some studies have shown an increased risk of possible nephrotoxicity with the use of larger doses of VCN [21]. The common dilemma encountered by clinicians is whether targeting an AUC:MIC of >400 outweighs the risk of possible nephrotoxicity.

Despite the recommendation to use 15-20 mg/Kg TBW, the guidelines caution that even using such doses and targeting a VCN serum trough concentration of 15-20 mg/L may not achieve an appropriate AUC:MIC goal. A recent study compared the success rate of achieving a VCN AUC:MIC of >400 by using a weight and CrCl based nomogram with patients who received 15-20 mg/Kg/dose (frequency based on CrCl) [22]. Doses up to 1250 mg every 8 hours (3750 mg daily) were utilized in the nomogram group in order to achieve the goal AUC:MIC of >400. Patients who were dosed based on the nomogram were 2 times as likely to achieve the AUC:MIC goal and were 2 times less likely to experience a VCN serum trough concentration <15 mg/L. The nomogram group was also approximately 4 times less likely to experience a steady-state VCN trough concentration <10 mg/L [22]. These results support the claim that dosing patients based on 15-20 mg/Kg may not be adequate to achieve the PD goal needed for VCN efficacy. In a separate study which examined the association between VCN AUC:MIC and the mortality risk in patients with MRSA bacteremia and endocarditis, an AUC:MIC ratio of <211 was associated with a greater than four-fold increase in attributable mortality compared to patients with an AUC:MIC of >211 [23]. Of note, patients in the AUC:MIC of <211 had an average dose of 16 mg/Kg/day while patients in the AUC:MIC >211 group had an average VCN dose of 22 mg/Kg/day thus further supporting the need for aggressive dosing of VCN in all patients particularly obese patients who would have a significantly lower AUC compared to a non-obese patient if given the a lower mg/kg/day VCN dose [23].

A recent study of VCN in obese patients aimed to compare the ability of two various VCN doses to attain target trough levels and the incidence of nephrotoxicity [24]. A new VCN dosing regimen developed specifically for obese patients was evaluated using a loading dose of 20–25 mg/kg based on ABW, followed by maintenance doses of 10 mg/kg every 12 hours, or 15 mg/kg every 24 hours, compared to an original protocol of a loading dose followed by 15 mg/kg every 8-12 hours based on ABW. Obese patients in the study were those weighing over 100 kg, with TBW exceeding 140% of IBW. 74 patients were evaluated using the revised protocol, compared with 64 patients who received the original protocol. First target trough obtained rates were 59% with the revised protocol, compared with 36% with the original protocol (p=0.006). These findings suggest loading doses of 20–25 mg/kg are effective for utilization in an obese patient population. In addition, VCN dosed at 10 mg/kg every 12 hours resulted in a subtherapeutic trough of <10 mg/L in 23% of the patients while 15 mg/Kg given every 8-12 hours resulted in 9% of the patients with a subtherapeutic VCN trough <10
Use of vancomycin loading dose

Administering a VCN loading dose helps achieve a AUC:MIC ratio of at least 400 and a therapeutic VCN trough concentration within the initial 24 hours of therapy which can be correlated to improved clinical outcomes and accelerated bacterial eradication. This has been supported by a study that found that delayed treatment was found to be an independent and strong predictor for mortality in patients with MRSA bacteremia [25].

The effectiveness of utilizing loading doses based on TBW in obese patients has begun to show improved clinical outcomes as it ensures an earlier achievement of AUC/MIC ratio >400 mcg/(h/mL) [19]. An additional study aimed to determine the percentage of critical patients in an analysis revealed significant correlation between dose in milligrams per kilogram based on TBW and the resultant trough concentration in this specific population. The majority of current studies focus on non-obese patients to determine the most appropriate doses and PD goals in their obese population. The most significant adverse effects attributed to VCN therapy are nephrotoxicity and red-man syndrome. Both adverse effects have significantly decreased in incidence over the past decade following improved formulation methods and increased VCN purity from 70% to 95% [21,31,32]. VCN nephrotoxicity has been attributed to renal tubular ischemia of the proximal tubule cells following oxidative effects of VCN [33]. Studies have shown that the incidence of VCN nephrotoxicity ranges from <10% when administered alone and up to as high as 40% when combined with other nephrotoxic medications [34]. To the knowledge of the authors, only one study to date has assessed the incidence of VCN induced nephrotoxicity in obese patients. In this recently published study which was discussed previously, nephrotoxicity correlated with initial VCN trough concentrations of >15 mg/L, however, it was not observed in patients who received maintenance doses >4 g per day [24]. This finding may suggest that the safety profile for the use of VCN in doses of 4 g per day or greater may differ in obese patients compared to non-obese patients. Many clinicians are hesitant to use VCN doses larger than 4 gm per day based on the results of a previous study which had shown that VCN in doses >4 g per day were associated with an increased incidence of nephrotoxicity (hazard ratio (HR) of 4.37 (2.96-6.45, p=0.001) especially in obese patients as the same study showed that a weight of ≥ 101.4 Kg was also associated with increased risk of nephrotoxicity (HR 3.44, range of 2.40-4.93, p=0.001) [21]. One suggested approach is to administer larger doses of vancomycin at a maximum of mg/h thus providing the patient with the optimal dose while avoiding a toxic peak concentration [30]. More recent studies aimed to specifically to address the efficacy and adverse events of VCN in obese patient will hopefully guide the future approach to how VCN should be dosed and monitored in this population.

Conclusion

More VCN PK and PD studies need to be conducted in obese patients as the incidence of obesity is at an all-time high. These studies will help guide clinicians especially physicians and pharmacists as to determine the most appropriate doses and PD goals in their obese population. The majority of current studies focus on non-obese patients which provide us with a good starting point and guide as to what need to be discovered about the variability in PK and PD in obese patients compared to their non-obese counterparts. At this time, it prudent that clinicians apply the PD goals which have been studied in mixed or non-obese population to the obese population keeping in mind that obese patients will likely require both larger loading and maintenance doses while receiving vancomycin more frequently. Fortunately, vancomycin induced nephrotoxicity is mostly reversible, and therefore clinicians should be aggressive with vancomycin therapy to ensure efficacy until VCN serum concentrations can be obtained from the patients and appropriate dosage adjustments can be made.

References